Direct-acting antivirals for hepatitis C do not increase the risk of hepatocellular carcinoma recurrence after locoregional therapy or liver transplant waitlist dropout
2020 ◽
Vol 52
(8)
◽
pp. 2450-2453
◽
2018 ◽
Vol 113
(Supplement)
◽
pp. S547-S548
2018 ◽
Vol 30
(4)
◽
pp. 368-375
◽